Predicted protein targets (top 2)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR2 | Q92731 | 20/20 | 1.00 |
| ▸ | ESR1 | P03372 | 19/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6343363 | 0.86 | ESR2 (1.00) | ESR2ESR1 | |
| SCHEMBL6334144 | 0.86 | ESR2 (1.00) | ESR2ESR1 | |
| SCHEMBL6335003 | 0.85 | ESR2 (0.75) | ESR2ESR1 | |
| SCHEMBL6342654 | 0.85 | ESR2 (1.00) | ESR2ESR1 | |
| SCHEMBL6333209 | 0.83 | ESR2 (1.00) | ESR2ESR1 | |
| SCHEMBL6335505 | 0.83 | ESR2 (0.79) | ESR2ESR1 | |
| SCHEMBL6335499 | 0.83 | ESR2 (0.79) | ESR2ESR1 | |
| SCHEMBL6333274 | 0.82 | ESR1 (1.00) | ESR2ESR1 | |
| SCHEMBL6335414 | 0.81 | ESR2 (0.85) | ESR2ESR1 | |
| SCHEMBL6342041 | 0.78 | ESR2 (0.76) | ESR2ESR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6943162-B2 | Osteoporosis; cardiovascular disorders; anticancer agents;incontinence | SMITHKLINE BEECHAM CORPORATION (US) | 2005-09-13 | — | — | US | claimed |
| US-20040072829-A1 | Piperazinyltriazines as estrogen receptor modulators | SMITHKLINE BEECHAM CORPORATION | 2004-04-15 | — | — | US | claimed |
| WO-2002072561-A1 | PIPERAZINYLTRIAZINES AS ESTROGEN RECEPTOR MODULATORS | SMITHKLINE BEECHAM CORPORATION (US) | 2002-09-19 | — | — | WO | claimed |
| US-6943162-B2 | Osteoporosis; cardiovascular disorders; anticancer agents;incontinence | SMITHKLINE BEECHAM CORPORATION (US) | 2005-09-13 | — | — | US | disclosed |
| US-20040072829-A1 | Piperazinyltriazines as estrogen receptor modulators | SMITHKLINE BEECHAM CORPORATION | 2004-04-15 | — | — | US | disclosed |
| WO-2002072561-A1 | PIPERAZINYLTRIAZINES AS ESTROGEN RECEPTOR MODULATORS | SMITHKLINE BEECHAM CORPORATION (US) | 2002-09-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040072829-A1 | Piperazinyltriazines as estrogen receptor modulators | GPER1, ESR2, ESR1 | ESR2 2/4885ESR1 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.